Repaglinide metabolism by human hepatocytes reveals CYP2C8 dominance and misassignment of CYP3A4 by liver subcellular fractions and recombinant enzymes
Drug Metabolism and Disposition · 2026-10 · 54 (10) · 100400
DOI: 10.1016/j.dmd.2026.100400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-10. Verfasst von Tashinga E Bapiro. Beteiligte Einrichtung: DMPK, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom. Electronic address: tashinga.bapiro1@astrazeneca.com. Hauptthemen laut MEDLINE: Hepatocytes, Cytochrome P-450 CYP3A, Cytochrome P-450 CYP2C8, Piperidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: AstraZeneca PLC.
Abstract (Originalsprache)
Repaglinide is an antidiabetic agent and Food and Drug Administration-endorsed clinical CYP2C8 probe with a well characterized human disposition profile in which a dicarboxylic acid, M2, is the main metabolite accounting for 66% of the administered dose. The remainder is distributed among M1 (4%), unchanged repaglinide (2%), M4 (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- DMPK, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom. Electronic address: tashinga.bapiro1@astrazeneca.com.
Förderung
- AstraZeneca PLC
Zitieren
APA
Bapiro, T. E. (2026). Repaglinide metabolism by human hepatocytes reveals CYP2C8 dominance and misassignment of CYP3A4 by liver subcellular fractions and recombinant enzymes. Drug Metabolism and Disposition, 54(10), 100400. https://doi.org/10.1016/j.dmd.2026.100400
Vancouver
Bapiro TE. Repaglinide metabolism by human hepatocytes reveals CYP2C8 dominance and misassignment of CYP3A4 by liver subcellular fractions and recombinant enzymes. Drug Metabolism and Disposition. 2026;54(10):100400. doi:10.1016/j.dmd.2026.100400
BibTeX
@article{Bapiro2026,
author = {Bapiro, Tashinga E},
title = {Repaglinide metabolism by human hepatocytes reveals CYP2C8 dominance and misassignment of CYP3A4 by liver subcellular fractions and recombinant enzymes},
journal = {Drug Metabolism and Disposition},
year = {2026},
volume = {54},
number = {10},
pages = {100400},
doi = {10.1016/j.dmd.2026.100400}
}
EUVIMED